MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jncics/pkag048

Медицинская библиотека · JNCI cancer spectrum · 2026

Financial reimbursement for clinical trial participation costs: a pilot feasibility study.

Williams Courtney P, Henderson Nicole L, Jahan Nusrat, Stringer-Reasor Erica, Azuero Andres, Pisu Maria, Arend Rebecca C, Rocque Gabrielle B

Клиническое исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

Clinical trial participants rarely represent the real-world treatment population, potentially due to costs associated with participation. Monetary reimbursement for trial-related costs could address financial barriers to trial recruitment and retention.

METHODS

This mixed-methods, pilot, feasibility study provided financial reimbursement to women with breast cancer participating in a clinical trial. Patients were reimbursed $1000/month during their first 4 months of trial participation, surveyed biweekly to assess changes in financial toxicity, and then interviewed to explore the effects of receiving reimbursement on trial-related costs and recruitment and retention. Mixed-effect modeling and thematic analysis were completed. Feasibility was defined as 80% retention of patients on the reimbursement study, with those retained completing 75% of surveys.

RESULTS

Of 39 consented patients, 33 patients completed the pilot study (85% retention, 100% survey completion). Patients were a median 52 years old (interquartile range = 44-59), 48% Black, 67% privately insured, and 42% found it difficult to live on their current income. Patient financial toxicity modestly decreased. Patients (n = 32) reported using the reimbursement to pay for trial visit-related food, transportation, caregiver expenses, and out-of-pocket medical costs. Patients felt receiving reimbursement affected trial retention more so than recruitment, stating "I would have enrolled regardless … [but knowing] it wasn't going to place a financial strain on us because of these reimbursements. … It made it easier for me to feel good about continuing."

CONCLUSION

Reimbursement for clinical trial-related costs is feasible, suggests decreases in financial toxicity, and is a promising approach to improve trial retention outcomes in women with breast cancer.

CLINICALTRIALS.GOV ID: NCT05871125.

Для цитирования: Williams Courtney P, Henderson Nicole L, Jahan Nusrat, Stringer-Reasor Erica, Azuero Andres, Pisu Maria, Arend Rebecca C, Rocque Gabrielle B. Financial reimbursement for clinical trial participation costs: a pilot feasibility study.. JNCI cancer spectrum. 2026. DOI: 10.1093/jncics/pkag048.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.